SET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia

Beidel, Déborah C.; Turner, Samuel M.; Sallee, Floyd R.; Ammerman, Robert T.; Crosby, Lori A.; Pathak, Sanjeev

doi:10.1097/chi.0b013e318154bb57

Cited by 192 publications

(144 citation statements)

References 30 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…The diagnostic interview was repeated at posttreatment using the same procedure. Further information on study procedures, treatments, and inclusion criteria have been reported elsewhere (Beidel et al 2007). …”

Section: Methodsmentioning

confidence: 99%

“…Thus, this sample was culled from a larger sample of 139 dyads. Detailed information on demographic and clinical characteristics for the total sample has been reported elsewhere (Beidel et al 2007). …”

Section: Participantsmentioning

confidence: 99%

“…Participants included 81 parent-child (7-16 years old [M= 11.75,SD=2.57]; 39 girls, 42 boys) dyads for which the child was receiving treatment as part of a multisite controlled trial comparing pharmacological (fluoxetine) and behavioral (Social Effectiveness Therapy for Children [SET-C]; Beidel et al 2000) treatments for social phobia (see Beidel et al 2007). Recruitment occurred through media announcements (newspaper, radio) or through referrals from local mental health professionals.…”

Section: Participantsmentioning

confidence: 99%

“…First, observed high rates of reporting disagreements within clinic samples of anxious children are commonly reported (Choudhury et al 2003;Grills and Ollendick 2003;Rapee et al 1994). Second, controlled treatment trials for childhood anxiety commonly use outcome measures from multiple informants (e.g., Beidel et al 2007;Kendall 1994;Silverman et al, 1999a, b;Weisz et al 2005). Third, informant disagreements occur at pretreatment, posttreatment, and longitudinal follow-up (Safford et al 2005).…”

mentioning

confidence: 99%

“…We addressed this question using data from a multisite controlled clinical trial of psychological and pharmacological treatments for childhood social phobia (Beidel et al 2007). On the assumption that we would identify the low-to-moderate levels of agreement commonly observed in prior work (De Los Reyes and Kazdin 2005), we predicted that pretreatment parent-child reporting discrepancies would predict posttreatment discrepancies.…”

mentioning

confidence: 99%

See 4 more Smart Citations

The Relations among Measurements of Informant Discrepancies within a Multisite Trial of Treatments for Childhood Social Phobia

Reyes

Alfano

Beidel

2009

J Abnorm Child Psychol

Self Cite

View full text Add to dashboard Cite

Discrepancies between informants' reports of children's behavior are robustly observed in clinical child research and have important implications for interpreting the outcomes of controlled treatment trials. However, little is known about the basic psychometric properties of these discrepancies. This study examined the relation between parent-child reporting discrepancies on measures of child social phobia symptoms, administered before and after treatment for social phobia. Participants included a clinic sample of 81 children (7-16 years old [M=11.75, SD=2.57]; 39 girls, 42 boys) and their parents receiving treatment as part of a multisite controlled trial. Pretreatment parent-child reporting discrepancies predicted parent-child discrepancies at posttreatment, and these relations were not better accounted for by the severity of the child's pretreatment primary diagnosis. Further, treatment responder status moderated this relation: Significant relations were identified for treatment non-responders and not for treatment responders. Overall, findings suggest that informant discrepancies can be reliably employed to measure individual differences over the course of controlled treatment trials. These data provide additional empirical support for recent work suggesting that informant discrepancies can meaningfully inform understanding of treatment response as well as variability in treatment outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Participantsmentioning

confidence: 99%

Section: Participantsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The Relations among Measurements of Informant Discrepancies within a Multisite Trial of Treatments for Childhood Social Phobia

Reyes

Alfano

Beidel

2009

J Abnorm Child Psychol

Self Cite

View full text Add to dashboard Cite

show abstract

Burden of Anxiety Disorders in Pediatric Medical Settings

Ramsawh¹,

Chavira²,

Stein³

2010

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

Medication and Cognitive Behavioral Therapy for Pediatric Anxiety Disorders

2017

View full text Add to dashboard Cite

Anxiety disorders are among the most prevalent pediatric behavioral health conditions, affecting roughly 32% of youths prior to adulthood, and associated with impaired functioning that can continue into adulthood and increase in severity. 1,2 In this issue of JAMA Pediatrics, Wang et al 3 report an updated meta-analysis evaluating the comparative efficacy of cognitive behavioral therapy (CBT) and pharmacotherapy for pediatric anxiety disorders. Results supported the efficacy of CBT, selective serotonin reuptake inhibitors (SSRIs), and their combination; limited support was provided for serotonin-norepinephrine reuptake inhibitors (SNRIs). We briefly review the evidence followed by implementation issues.Results of the meta-analysis indicate that CBT and SSRIs were each more likely to result in diagnostic remission/treatment response compared with wait list/no treatment and pill placebo, respectively. Combined CBT and medication led to greater improvements in anxiety symptoms compared with CBT alone (2 studies) or medication alone (1 study). Comparison of CBT and SSRIs (2 studies) indicated greater declines in anxiety (symptoms and diagnostic remission) among CBT-treated vs SSRI-treated children. 4,5 Some, but less, support was found for SNRIs on a few outcomes in some trials; there was no support for tricyclic medications, benzodiazepines, or buspirone. Adverse events and treatment dropout were more common during pharmacotherapy compared with CBT, although SSRIs and pill placebo did not statistically differ in dropout rates, dropout due to adverse events, or any specific adverse events. With regard to psychiatric adverse events, no suicide deaths or attempts were reported in any study and suicidal behavior appeared to be less than in

show abstract

SET-C Versus Fluoxetine in the Treatment of Childhood Social Phobia

Cited by 192 publications

References 30 publications

The Relations among Measurements of Informant Discrepancies within a Multisite Trial of Treatments for Childhood Social Phobia

The Relations among Measurements of Informant Discrepancies within a Multisite Trial of Treatments for Childhood Social Phobia

Burden of Anxiety Disorders in Pediatric Medical Settings

Medication and Cognitive Behavioral Therapy for Pediatric Anxiety Disorders

Contact Info

Product

Resources

About